Xylazine toxicity - Symptoms, Causes, Treatment & Prevention

Overview

Xylazine is a potent, non‑opioid sedative originally developed for use in veterinary medicine (mainly to tranquilize large animals such as cattle, horses, and goats). In recent years, illicit manufacturers have been adding xylazine to street‑level opioids—especially fentanyl and heroin—to prolong the high and enhance the “body high.” This practice has created a new public‑health problem known as xylazine toxicity or “tranq‑related overdose.”

• Who it affects: Primarily people who use illicit opioids, but anyone exposed to contaminated drug supplies, including people who are incarcerated, experiencing homelessness, or living in regions with high fentanyl prevalence.
• Prevalence: According to the U.S. Centers for Disease Control and Prevention (CDC), xylazine was detected in approximately 13 % of fentanyl‑related overdose deaths in 2023, a steep rise from <1 % in 2019. Similar trends are reported in Canada, Brazil, and parts of Europe.

Symptoms

Because xylazine is a central‑alpha‑2‑adrenergic agonist, its clinical picture combines profound sedation with cardiovascular and respiratory depression. Symptoms may appear within minutes of ingestion, inhalation, or injection and can last from 30 minutes to several hours.

Neurologic / Psychiatric

• Severe drowsiness or “coma‑like” state – the person may be unresponsive to verbal stimuli.
• Confusion, disorientation – especially when combined with opioids.
• Potential hallucinations or delirium – reported in mixed‑substance overdoses.

Cardiovascular

• Bradycardia – heart rate < 60 bpm, sometimes < 40 bpm.
• Hypotension – systolic < 90 mmHg; orthostatic drops are common.
• Arrhythmias – especially when xylazine is combined with stimulants.

Respiratory

• Respiratory depression – shallow, slow breathing (RR < 12/min).
• Apnea – can be transient but is life‑threatening.

Dermatologic / Peripheral

• Necrotic skin ulcers – “skin popping” from injecting xylazine‑contaminated solutions leads to painless, well‑circumscribed ulcers, often on the arms, torso, or legs. These may develop weeks after the exposure.
• Vasoconstriction‑related ischemia – bluish discoloration of fingertips or toes.

Gastrointestinal

• Nausea / vomiting – especially when combined with opioids.
• Constipation – due to decreased gut motility.

Other

• Hypothermia – body temperature < 35 °C in severe cases.
• Muscle weakness / flaccidity.

Causes and Risk Factors

Xylazine toxicity occurs when the drug enters the human body in a dose that exceeds the individual’s tolerance. The most common pathways are:

1. Illicit drug contamination – xylazine is mixed with fentanyl, heroin, or counterfeit prescription opioids. Users often do not know it is present.
2. Injecting adulterated solutions – “skin‑popping” or intravenous injection delivers high concentrations directly to the bloodstream.
3. Inhalation of vaporized mixtures – increasingly reported with “flash‑cooking” techniques.

Risk Factors

• History of opioid use disorder (OUD).
• Recent use of illicit fentanyl or heroin.
• Polysubstance use (e.g., combining stimulants, benzodiazepines, or alcohol).
• Homelessness or unstable housing that limits access to clean injection equipment.
• Geographic areas with high xylazine detection in the drug supply (e.g., Northeastern U.S., major Canadian cities).

Diagnosis

Diagnosing xylazine toxicity is challenging because standard toxicology screens often do not include xylazine. The evaluation relies on a combination of history, clinical findings, and targeted laboratory testing.

Clinical Assessment

• Rapid assessment of airway, breathing, circulation (ABCs).
• Focused physical exam for pinpoint pupils (opioid sign) together with the unique skin ulcer findings.
• Ask about recent drug use, especially fentanyl or heroin, and whether the drug source is known to contain “tranq.”

Laboratory Tests

• Serum/urine toxicology – Specialized LC‑MS/MS (liquid chromatography‑tandem mass spectrometry) can detect xylazine at concentrations as low as 0.1 ng/mL. Some major medical examiner offices now include xylazine in their panels.
• Basic metabolic panel – to identify hypotension, hypoglycemia, renal impairment.
• Arterial blood gas (ABG) – assesses respiratory depression and acidosis.
• Cardiac monitoring – continuous ECG for bradyarrhythmias.

Imaging

• Chest X‑ray or CT if respiratory compromise is suspected.
• A wound culture or imaging for necrotic ulcers to rule out secondary infection.

Treatment Options

There is no specific antidote for xylazine. Management focuses on supportive care, reversal of co‑administered opioids, and mitigation of complications.

Emergency Stabilization

1. Airway & Breathing – Provide supplemental oxygen; consider bag‑valve‑mask ventilation or endotracheal intubation if respiratory drive is absent.
2. Circulation – Position the patient supine, apply cardiac monitoring, and give isotonic fluids (e.g., 1‑2 L normal saline) for hypotension.
3. Opioid antagonist – Administer naloxone 0.4‑2 mg IV/IM/IN. While naloxone reverses opioid effects, it does not counteract xylazine‑induced sedation; multiple doses may be required because the xylazine effect can outlast the opioid block.

Pharmacologic Measures

• Atropine – 0.5 mg IV for symptomatic bradycardia (< 50 bpm) or hypotension refractory to fluids.
• Vasopressors – Norepinephrine infusion if hypotension persists despite fluids and atropine.
• Analgesia & Sedation – If the patient is agitated after naloxone, short‑acting benzodiazepines (e.g., lorazepam) can be used, but caution is needed because they may worsen respiratory depression.
• Wound care – Debridement, topical antimicrobial agents, and referral to a wound‑care specialist for chronic ulcers.

Adjunctive & Long‑Term Measures

• Observation – Patients should be observed for at least 6 hours after the last dose, as xylazine’s half‑life (≈ 2–3 hours) can be prolonged in renal/hepatic impairment.
• Consult addiction services – Immediate referral to medication‑assisted treatment (MAT) (buprenorphine, methadone, or naltrexone) reduces the chance of repeat exposure.
• Vaccinations – Hepatitis A/B and tetanus boosters for those with skin ulcers.

Living with Xylazine Toxicity

For individuals who have experienced xylazine toxicity, ongoing management is essential to prevent recurrence and address the physical sequelae.

Daily Management Tips

• Medication‑Assisted Treatment (MAT) – Stay engaged in a supervised MAT program; buprenorphine or methadone reduces cravings for illicit opioids.
• Use of fentanyl test strips – While not detecting xylazine, they can identify fentanyl‑containing products, prompting caution.
• Hydration & Nutrition – Adequate fluid intake supports renal clearance; a balanced diet promotes wound healing.
• Wound care routine – Clean ulcers with saline, apply sterile dressings, and monitor for signs of infection (redness, swelling, fever).
• Regular medical follow‑up – Quarterly visits with a primary care provider or addiction specialist to track blood pressure, heart rate, and mental health.
• Mental health support – Counseling, peer‑support groups, or cognitive‑behavioral therapy (CBT) to address trauma and reduce substance use triggers.

Tools & Resources

• National Helpline: 1‑800‑662‑HELP (4357) – free, confidential support for substance‑use disorders.
• Local harm‑reduction programs – many offer sterile injection supplies, wound‑care kits, and on‑site testing.
• Mobile apps (e.g., “Sax – Safe” or “FindHelp”) that locate nearby treatment centers.

Prevention

Preventing xylazine toxicity centers on reducing exposure to contaminated drug supplies and addressing the broader opioid epidemic.

1. Supply‑Side Interventions – Law‑enforcement and public‑health partnerships to monitor drug seizures for xylazine and disseminate alerts.
2. Harm‑Reduction Services – Distribution of fentanyl test strips, sterile syringes, and education about “unknown adulterants.”
3. Medication‑Assisted Treatment Expansion – Increasing access to buprenorphine waivers for primary‑care clinicians.
4. Public Education – Community campaigns highlighting the rising trend of “tranq” in street drugs and encouraging people to seek help before using.
5. Community‑Based Overdose Response – Training lay responders in naloxone use and encouraging them to call emergency services even if the person appears “awake” after naloxone.

Complications

If left untreated, xylazine toxicity can lead to severe, sometimes irreversible outcomes.

• Fatal respiratory or cardiac arrest – especially when combined with potent opioids.
• Permanent skin loss and infection – necrotic ulcers may become gangrenous, requiring surgical debridement or amputation.
• Sepsis – secondary bacterial infection from open wounds.
• Chronic pain and disability – nerve damage from ischemic ulcers.
• Psychiatric sequelae – post‑traumatic stress disorder (PTSD), depression, and heightened anxiety after overdose experiences.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Xylazine (Animal tranquilizer) – Toxicity.”; CDC. “Fentanyl and other synthetic opioids data.”; National Institute on Drug Abuse (NIDA). “Illicitly mixed opioids.”; WHO. “Guidelines for the management of substance use disorders.”; Cleveland Clinic. “Harm reduction and overdose prevention.”; JAMA Network Open. “Tranquilizer‑related overdose deaths in the United States, 2019‑2022.”